-
Shanghai promotes innovative drugs and innovative medical devices into medical insurance and commercial insurance
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Recently, Shanghai issued "Several Policies and Measures for Shanghai to Accelerate the Construction of a Global Biomedical R&D Economy and Industrialization Highland" to support the development of Shanghai's biomedical R&D economy and put forward a number of policies and measures to accelerate the construction of a global biomedical R&D economy and industrialization highland.
-
The liver cancer test was full of joy and sorrow, and the biliary tract tumor made a milestone breakthrough
Time of Update: 2022-10-03
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
-
How to effectively administer drugs when encountering Pseudomonas aeruginosa
Time of Update: 2022-02-23
Pseudomonas aeruginosa infection in patients with cystic fibrosis:scientific evidence regarding clinical impact,diagnosis,and treatment.
Laboratory diagnosis, antimicrobial treatment and nosocomial infection control of extensively drug-resistant gram-negative bacterial infection: Chinese expert consensus [J].
-
Qilu wins 1 billion injection of recombinant human follicle stimulating hormone injection
Time of Update: 2021-12-25
A few days ago, the official website of the State Food and Drug Administration showed that Qilu Pharmaceutical's recombinant human follicle stimulating hormone for injection was approved for marketing.
-
The second
Time of Update: 2021-12-24
Source: NextPharmaAt present, there are 3 indications approved in China for the research of tocilizan antigen, namely: adult rheumatoid arthritis, systemic juvenile idiopathic arthritis and cytokine release syndrome .
Among them, domestic companies that develop tocilizumab biosimilar drugs include Hisun Pharmaceuticals, Livzon Pharmaceuticals, and Biotech Biopharmaceuticals .
-
Request for comments on the statistical guidelines for clinical research of rare disease drugs
Time of Update: 2021-12-05
Clinical research of rare disease drugs often faces problems such as difficulty in enrollment, long enrollment time, limited sample size, high heterogeneity of enrolled subjects, and lack of effective treatment methods, which require higher quality of clinical research .
-
The first provincial-level cross-regional procurement alliance for Chinese patent medicine is coming
Time of Update: 2021-08-27
Chinese medicine into the Central Purchasing large variety of sales further pressure In recent years, affected by the adjustment of medical insurance policies and the gradual refinement of the rational drug use policy in hospitals , the overall growth rate of the Chinese patent medicine market has continued to slow down .
-
Ascent Pharma's third-generation BCR-ABL inhibitor plans to be included in breakthrough treatment products
Time of Update: 2021-04-28
Source: Guanlan PharmaceuticalAccording to the latest announcement by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China, Yasheng Pharmaceutical's wholly-owned subsidiary, Shunjian Biologics, a new class 1 drug, nectinib tablets (HQP1351, also known as oribatinib), will be included in the breakthrough treatment Variety, the proposed indication is: for the treatment of chronic myelogenous leukemia (CML) patients who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors.
-
Merck's K drug is approved for new indications in the United States and Europe, Ogalon acquires Alydia
Time of Update: 2021-04-24
"K medicine" hits a wall in the United States"K medicine" hits a wall in the United StatesA few days ago, the US Food and Drug Administration (FDA) issued a complete response letter (CRL) to Merck for the use of Keytruda in the treatment of high-risk early triple-negative breast cancer (TNBC) for supplementary biological license applications (sBLA).
-
10 billion HER2 single-anti-market quto bead single anti-biosynthic drugs can usher in spring
Time of Update: 2021-03-11
data source: CSCO Breast Cancer Guidelines 2020 According to Frost and Sullivan cited in Sansheng National Health's prospectus, China's anti-HER2 single-drug market grew from about 1.4 billion yuan in 2014 to about 3.2 billion yuan in 2018, with a compound annual growth rate of 23.9%.
-
Fangsheng Pharmaceutical Montessin Dispersion is evaluated by generic drug consistency
Time of Update: 2021-03-10
3, the market similar products according to Mienet data show that as of this announcement date, a total of 23 manufacturers of Montessilo scattered through the State Drug Administration generic drug quality and efficacy consistent evaluation and approval.
-
Fosun Pharma YP01001 capsule clinical trial application accepted
Time of Update: 2021-01-24
The new drug is an innovative small molecule chemical drug intended to be used to treat advanced solid tumors (liver cancer, stomach cancer, etc.); as of the date of this announcement, the new drug listed in China (excluding Hong Kong, Macao and Taiwan, the same as between 2007) has methyl sulfonate lenphatini capsules and so on.
-
The successful completion of Phase 3 registration research by Hua-Li Pharmaceuticals is accelerating the NDA process
Time of Update: 2021-01-16
the DAWN study, the second phase 3 registered clinical study of Huali medicine, lasted 53 weeks, including 52 weeks of treatment and the next week of safe follow-up, in 767 patients with type 2 diabetes, with the aim of studying the effectiveness and safety of Dozagliatin (75 mg/time, twice daily).
-
Fosun plans to raise nearly $5 billion to focus on the development of innovative drugs such as the new crown vaccine
Time of Update: 2020-12-29
and the funds raised by this non-public offering of shares, Fosun will invest 2.2 billion yuan in clinical development of innovative drugs, commercial licensing, licensing of the introduction of project research and development milestones and some product launch preparation related follow-up costs.
-
The first cancer electric field therapy Chinese real-world data from the group
Time of Update: 2020-12-06
BEIJING, Sept. 13 (Xinhua Li Yanan) A forward-looking, one-arm observational study evaluating the treatment of tumor electric field in patients with glioblastoma (GBM) in China was recently presented
